We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Tissue Regenix Group Plc | LSE:TRX | London | Ordinary Share | GB00BNTXR104 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.30 | 2.16% | 61.50 | 61.00 | 62.00 | 61.50 | 61.50 | 61.50 | 22 | 08:00:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 24.48M | -2.7M | -0.0382 | -16.10 | 43.4M |
From Apr 2019 to Apr 2024
TIDMTRX
RNS Number : 0223R
Tissue Regenix Group PLC
06 December 2016
Tissue Regenix Group plc
DermaPure secures GPO agreement with Premier, Inc.
Leeds, 06 December 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces Tissue Regenix Wound Care, Inc. has secured a Group Purchasing Organisation (GPO) contract with Premier Inc., a leading healthcare improvement company.
DermaPure has been awarded this contract under a 'Breakthrough Technology Agreement', which is awarded by the GPO after a thorough four step review process is completed and it is determined that the technology offers unique attributes to the other available treatment options.
The Premier alliance is comprised of approximately 3,600 U.S. based hospitals and 120,000 other healthcare providers which will now have contracted access to DermaPure(R).
Antony Odell, CEO, Tissue Regenix Group plc commented: "Approval under Premier's Breakthrough Technology Agreement marks a significant milestone for DermaPure(R). This confirms the unique characteristics of our patented dCELL(R) Technology, the powerful clinical evidence we have collected, and the remarkable outcomes it achieves in real world clinical situations."
For more Information:
Tissue Regenix Group plc Tel: 0330 Caitlin Pearson Corporate Communications 430 3073 Officer ========================================== =========== Jefferies International Ltd Tel: 020 Simon Hardy / Harry Nicholas 7029 8000 ========================================== ===========
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL(R)') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL(R) technology platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTTABLTMBAMBLF
(END) Dow Jones Newswires
December 06, 2016 02:00 ET (07:00 GMT)
1 Year Tissue Regenix Chart |
1 Month Tissue Regenix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
